open access
Comparison of dosimetric variation between prostate IMRT and VMAT due to patient's weight loss: Patient and phantom study
open access
Abstract
Aim
This study compared the dosimetric impact between prostate IMRT and VMAT due to patient's weight loss.
Background
Dosimetric variation due to change of patient's body contour is difficult to predict in prostate IMRT and VMAT, since a large number of small and irregular segmental fields is used in the delivery.
Materials and methods
Five patients with prostate volumes ranging from 32.0 to 86.5[[ce:hsp sp="0.25"/]]cm3 and a heterogeneous pelvis phantom were used for prostate IMRT and VMAT plans using the same set of dose–volume constraints. Doses in IMRT and VMAT plans were recalculated with the patient's and phantom's body contour reduced by 0.5–2[[ce:hsp sp="0.25"/]]cm to mimic size reduction. Dose coverage/criteria of the PTV and CTV and critical organs (rectum, bladder and femoral heads) were compared between IMRT and VMAT.
Results
In IMRT plans, increases of the D99% for the PTV and CTV were equal to 4.0[[ce:hsp sp="0.25"/]]±[[ce:hsp sp="0.25"/]]0.1% per cm of reduced depth, which were higher than those in VMAT plans (2.7[[ce:hsp sp="0.25"/]]±[[ce:hsp sp="0.25"/]]0.24% per cm). Moreover, increases of the D30% of the rectum and bladder per reduced depth in IMRT plans (4.0[[ce:hsp sp="0.25"/]]±[[ce:hsp sp="0.25"/]]0.2% per cm and 3.5[[ce:hsp sp="0.25"/]]±[[ce:hsp sp="0.25"/]]0.5% per cm) were higher than those of VMAT (2.2[[ce:hsp sp="0.25"/]]±[[ce:hsp sp="0.25"/]]0.2% per cm and 2.0[[ce:hsp sp="0.25"/]]±[[ce:hsp sp="0.25"/]]0.6% per cm). This was also true for the increase of the D5% for the right femoral head in a patient or phantom with size reduction due to weight loss.
Conclusions
VMAT would be preferred to IMRT in prostate radiotherapy, when a patient has potential to suffer from weight loss during the treatment.
Abstract
Aim
This study compared the dosimetric impact between prostate IMRT and VMAT due to patient's weight loss.
Background
Dosimetric variation due to change of patient's body contour is difficult to predict in prostate IMRT and VMAT, since a large number of small and irregular segmental fields is used in the delivery.
Materials and methods
Five patients with prostate volumes ranging from 32.0 to 86.5[[ce:hsp sp="0.25"/]]cm3 and a heterogeneous pelvis phantom were used for prostate IMRT and VMAT plans using the same set of dose–volume constraints. Doses in IMRT and VMAT plans were recalculated with the patient's and phantom's body contour reduced by 0.5–2[[ce:hsp sp="0.25"/]]cm to mimic size reduction. Dose coverage/criteria of the PTV and CTV and critical organs (rectum, bladder and femoral heads) were compared between IMRT and VMAT.
Results
In IMRT plans, increases of the D99% for the PTV and CTV were equal to 4.0[[ce:hsp sp="0.25"/]]±[[ce:hsp sp="0.25"/]]0.1% per cm of reduced depth, which were higher than those in VMAT plans (2.7[[ce:hsp sp="0.25"/]]±[[ce:hsp sp="0.25"/]]0.24% per cm). Moreover, increases of the D30% of the rectum and bladder per reduced depth in IMRT plans (4.0[[ce:hsp sp="0.25"/]]±[[ce:hsp sp="0.25"/]]0.2% per cm and 3.5[[ce:hsp sp="0.25"/]]±[[ce:hsp sp="0.25"/]]0.5% per cm) were higher than those of VMAT (2.2[[ce:hsp sp="0.25"/]]±[[ce:hsp sp="0.25"/]]0.2% per cm and 2.0[[ce:hsp sp="0.25"/]]±[[ce:hsp sp="0.25"/]]0.6% per cm). This was also true for the increase of the D5% for the right femoral head in a patient or phantom with size reduction due to weight loss.
Conclusions
VMAT would be preferred to IMRT in prostate radiotherapy, when a patient has potential to suffer from weight loss during the treatment.
Keywords
Prostate IMRT; Prostate VMAT; Patient' s weight loss; Treatment planning evaluation and dose–volume points


Title
Comparison of dosimetric variation between prostate IMRT and VMAT due to patient's weight loss: Patient and phantom study
Journal
Reports of Practical Oncology and Radiotherapy
Issue
Pages
272-278
Published online
2013-09-01
DOI
10.1016/j.rpor.2013.05.003
Bibliographic record
Rep Pract Oncol Radiother 2013;18(5):272-278.
Keywords
Prostate IMRT
Prostate VMAT
Patient's weight loss
Treatment planning evaluation and dose–volume points
Authors
James C.L. Chow
Runqing Jiang